Get the Stockscreener App
27.81
0.82%
0.22
Agios Pharmaceuticals Inc stock is traded at $27.81, with a volume of 283.82K.
It is up +0.82% in the last 24 hours and down -0.51% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$27.59
Open:
$27.76
24h Volume:
283.82K
Relative Volume:
0.27
Market Cap:
$1.63B
Revenue:
$54.03M
Net Income/Loss:
$-412.78M
P/E Ratio:
-3.9065
EPS:
-7.1189
Net Cash Flow:
$-377.29M
1W Performance:
+1.26%
1M Performance:
-0.51%
6M Performance:
-24.37%
1Y Performance:
-10.47%
1-Day Range:
$27.26
$28.19
1-Week Range:
$27.00
$28.97
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.79 | 1.62B | 54.03M | -412.78M | -377.29M | -7.1189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.39 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.11 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.05 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026 - Meyka
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND Approval And GCC Expansion - simplywall.st
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - Morningstar
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law ViolationsContact The Gross Law Firm for Details- AGIO - lelezard.com
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Sec - GuruFocus
Agios Pharmaceuticals: Worthy Of Accumulation (NASDAQ:AGIO) - Seeking Alpha
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides - AOL.com
Zacks Research Analysts Lift Earnings Estimates for AGIO - MarketBeat
Stock Analysis: Is Agios Pharmaceuticals Inc. stock showing strong momentum2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Why Agios Pharmaceuticals Inc. stock could benefit from AI revolutionShort Setup & Risk Managed Investment Entry Signals - Naître et grandir
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
FY2028 Earnings Forecast for AGIO Issued By Zacks Research - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why (AGIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell Alert: Washburn Theodore James Jr. Sells Shares of Agios Pharmaceuticals Inc (AGIO) - GuruFocus
AGIO: Citigroup Raises Price Target Amidst Continuous Buy Ratings | AGIO Stock News - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharmaceuticals (AGIO) Target Price Raised by Citi - GuruFocus
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - Morningstar
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by TD Asset Management Inc - MarketBeat
Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug - simplywall.st
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact The Gross Law Firm Regarding Potential Securities Law ViolationsAGIO - StreetInsider
Agios (AGIO) CMO logs tax-driven share sales and major new equity awards - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives large equity grants, sells shares for tax withholding - Stock Titan
AGIOS (AGIO) legal chief gains RSUs, options and sells shares for taxes - Stock Titan
Agios Pharmaceuticals (AGIO) CFO equity grants and tax-driven sales - Stock Titan
AGIOS (NASDAQ: AGIO) CCO reports new equity awards and tax-driven share sales - Stock Titan
Agios (AGIO) accounting officer sells shares to cover RSU tax withholding - Stock Titan
Agios (NASDAQ: AGIO) executive granted 14,000 RSUs and 52,000 options - Stock Titan
AGIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights A - GuruFocus
Agios Pharmaceuticals Highlights 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - National Today
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - Yahoo Finance
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND UAE Thalassemia Approval - simplywall.st
AGIO (Nasdaq: AGIO) reports RSU vesting and Brian Goff sale disclosure - Stock Titan
AGIO (NASDAQ: AGIO) insider resale notice for 5,218 shares on 03/02/2026 - Stock Titan
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Insider sale notice: 5,035 AGIO shares tied to RSU vesting (NASDAQ: AGIO) - Stock Titan
Insider sells and RSUs vest at AGIO (NASDAQ: AGIO) — 2,868 RSUs listed - Stock Titan
AGIO: Mitapivat’s thalassemia launch accelerates, with pipeline and regulatory catalysts ahead - TradingView
Agios' Pyrukynd® (mitapivat) approved for adults with thalassemia in the United Arab Emirates - marketscreener.com
Agios Pharmaceuticals (AGIO) Gains UAE Approval for Pyrukynd - GuruFocus
Vanguard Group Inc. Sells 77,143 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - Bitget
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - The Manila Times
UAE approves only treatment option for adults with thalassemia - Stock Titan
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Nigeria
Erste Asset Management GmbH Purchases 438,411 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Mar 05 '26 |
Sale |
27.80 |
2,959 |
82,260 |
5,141 |
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):